Liquidia Technologies, Inc. (NASDAQ:LQDA) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Jason Adair - Vice President, Corporate Development and Strategy Neal Fowler - Chief Executive Officer Rich Katz - Chief Financial Officer Shawn Glidden - Vice President Legal Affairs and Secretary Conference Call Participants Liana Moussatos - Wedbush Serge Belanger - Needham & Company Georgi Yordanov - Cowen and Company Operator Good afternoon, ladies and gentlemen. My name is Christy ...

Liquidia Technologies, Inc. (NASDAQ:LQDA) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Jason Adair – Vice President, Corporate Development and Strategy Neal Fowler – Chief Executive Officer Rich Katz – Chief Financial Officer Rob Roscigno – Senior Vice President-Product Development Shawn Glidden – Vice President Legal Affairs and Secretary Conference Call Participants Liana Moussatos – Wedbush Ken Cacciatore – Cowen and Company Roger Song – Jefferies Operator Good afternoon, ...

Liquidia Technologies, Inc. (NASDAQ:LQDA) Q4 2019 Results Earnings Conference Call March 11, 2020 8:00 AM ET Company Participants Jason Adair - Vice President, Corporate Development and Strategy Neal Fowler - Chief Executive Officer Richard Katz - Chief Financial Officer Robert Roscigno - Senior Vice President, Product Development Conference Call Participants Liana Moussatos - Wedbush Securities Ken Cacciatore - Cowen and Company Serge Belanger - Needham & Company Operator Good morning, ladies and gentlemen ...

LIQUIDIA Corporate Overview March 2020 Forward-Looking Statements 2 This presentation includes, and our response to various questions may include, forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The words "anticipate," "believe," "continue," "estima ...

Liquidia Technologies, Inc. (NASDAQ:LQDA) Q3 2019 Earnings Conference Call November 13, 2019 8:00 AM ET Company Participants Jason Adair - VP, Corporate Development and Strategy Neal Fowler - CEO Rich Katz - CFO Robert Roscigno - SVP, Product Development Conference Call Participants Liana Moussatos - Wedbush Ken Cacciatore - Cowen and Company Serge Belanger - Needham Roger Song - Jefferies Operator Good morning, ladies and gentlemen. My name is Shannon, and I will be your conference operator today. I would ...

Corporate Overview October 2019 Forward-Looking Statements 2 This presentation includes, and our response to various questions may include, forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The words "anticipate," "believe," "continue," "estimate," "e ...

Financial Data and Key Metrics Changes - Revenues for Q2 2019 were $8.1 million, a significant increase from $1 million in Q2 2018, primarily due to the recognition of previously deferred revenue related to the GSK collaboration [16][18] - Cost of sales increased to $0.8 million in Q2 2019 from $0.1 million in Q2 2018, reflecting sub-licensing fees associated with the GSK agreement [17] - R&D expenses rose to $10.7 million in Q2 2019 from $5.9 million in the prior year, driven by ongoing clinical costs related to LIQ861 [17] - General and administrative expenses were $2.4 million in Q2 2019, up from $2 million in Q2 2018, mainly due to employee-related expenses [18] - The net loss narrowed to $5.9 million in Q2 2019 from $6.3 million in Q2 2018, attributed to the recognition of $8.1 million in deferred revenue [18][19] - Cash at the end of Q2 2019 was $52.1 million, with 18.6 million shares outstanding [19] Business Line Data and Key Metrics Changes - LIQ861, an inhaled dry powder formulation of treprostinil, has shown a favorable safety and tolerability profile, with over 90% of patients remaining on therapy at the two-month mark [10][12] - LIQ865, a PRINT formulation of bupivacaine for postoperative pain, is on track for Phase 2 studies in the first half of 2020 [14] Market Data and Key Metrics Changes - The company has amended its agreement with GSK to pursue additional inhaled products using PRINT technology, expanding its pipeline opportunities [12][13] Company Strategy and Development Direction - The company aims to submit the NDA for LIQ861 by the end of 2019 and release additional longitudinal data from the INSPIRE trial in Q4 2019 [20][21] - The focus is on leveraging PRINT technology to build a robust portfolio of innovative programs, with an emphasis on inhaled therapies [21][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the therapeutic benefits of LIQ861 and the positive feedback from the PAH community [11][21] - The company is exploring various financing options to extend its cash runway beyond Q2 2020 [33][58] Other Important Information - The company is actively assessing partnership opportunities for ex-U.S. strategies and is open to various funding alternatives [42][58] Q&A Session Summary Question: What is the evolution of the PK human landscape for LIQ861? - Management indicated optimism about LIQ861's potential to replace and expand the inhaled therapy market, leveraging the convenience of a dry powder inhaler [25] Question: What additional 861 INSPIRE trial data will be available in Q4? - Management confirmed that longitudinal data will include adverse event data and secondary endpoints, consistent with previous reports [32] Question: What is the cash runway for the company? - The company has cash into the second quarter of 2020 and is exploring various financing options to extend its runway [33] Question: Has the pre-NDA meeting with the FDA been completed? - Management plans to schedule the pre-NDA meeting in early Q4, setting the stage for NDA filing by the end of the year [40] Question: What are the strategies for additional pipeline programs? - The company aims to build on its existing expertise and capabilities in inhaled therapies, focusing on differentiated molecules and sustained release capabilities [55]

Liquidia Technologies Inc. (NASDAQ:LQDA) Q1 2019 Earnings Conference Call May 2, 2019 8:00 AM ET Company Participants Jenny Kobin - IR Neal Fowler - CEO Tim Albury - CFO Robert Roscigno - SVP, Product Development & Program Lead for LIQ861 Conference Call Participants Stacy Ku - Cowen & Company Liana Moussatos - Wedbush Securities Serge Belanger - Needham & Company Chris Howerton - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Liquidia First Quarter 2019 Financial Results and Corporat ...

Corporate Overview Needham & Company's 18th Annual Healthcare Conference April 9, 2019 Forward-Looking Statements 2 This presentation includes, and our response to various questions may include, forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The wo ...

Liquidia Technologies Inc. (NASDAQ:LQDA) Q4 2018 Earnings Conference Call February 26, 2019 8:00 AM ET Company Participants Jenny Kobin - Investor Relations Neal Fowler - Chief Executive Officer Kevin Gordon - President and Chief Financial Officer Dr. Robert Roscigno - SVP of Product Development and Program Lead for LIQ861 Conference Call Participants Liana Moussatos - Wedbush Securities Serge Belanger - Needham & Company Chris Howerton - Jefferies Operator Good day ladies and gentlemen and welcome to the L ...